Novo Nordisk A/S vs Ralph Lauren Corp — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Ralph Lauren Corp trades at $375.67 (market cap $22.41B). The key difference: Novo Nordisk A/S is far larger — about 9.8× Ralph Lauren Corp's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | RL | |
|---|---|---|
Market Cap | $220.53B | $22.41B |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $414.25 |
52-Week Low | $35.29 | $283.34 |
Enterprise Value | $239.49B | $23.35B |
Dividend Yield | 3.63% | 0.99% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →